The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
PARP inhibition: A promising therapeutic target in ovarian cancer
Corresponding Author(s) : A Musella
Cellular and Molecular Biology,
Vol. 61 No. 6: Advances in molecular oncology: Closer analysis of recent breakthroughs
Abstract
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum- taxane -based chemotherapy and radical surgery. Despite several adjustments occurred in cytotoxic drug in last decades, most patients continue to relapse, and no significant enhancement has been reached in the overall survival. The development of drug resistance and the recurrence of disease have prompted the investigations of other targets that can be used in the treatment of ovarian cancers. Among such targets, polyadenosine diphosphate-ribose polymerase (PARP) represents a novel way to target specific patways involved in tumor growth. PARP accelerates the reaction of the polyADP-ribosylation of proteins implicated in DNA repair. PARP inhibitors have shown activity in cancers with BRCA mutations, with other deficient DNA repair genes or signaling pathways that modulate DNA repair, or in association with DNA damaging agents not involved in DNA repair dysfunction. A number of inhibitors for PARP has been developed, and such drugs are under investigation in clinical trials to identify their impact in the treatment of ovarian cancers. This review aims to summarize the recent researches and clinical progress on PARP inhibitors as novel target agents in ovarian cancer.
Keywords
Ovarian Cancer
PARP inhibitors
Target Therapies
Synthetic Lethality 1.
Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Casorelli, A., Domenici, L., Imperiale, L., Ruscito, I., Abdul Halim, T., Palaia, I., Di Donato, V., Pecorini, F., Monti, M., Muzii, L., & Panici, P. B. (2015). PARP inhibition: A promising therapeutic target in ovarian cancer. Cellular and Molecular Biology, 61(6), 44–61. Retrieved from https://mail.cellmolbiol.org/index.php/CMB/article/view/723
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX